Navigation Links
Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
Date:9/30/2009

ANN ARBOR, Mich., Sept. 30 /PRNewswire/ -- Incept BioSystems, Inc. ("Incept" or the "Company"), a privately-held biomedical device company using patented microfluidic technology developed at the University of Michigan, announced today that it has initiated the first U.S. human clinical trial of its proprietary SMART Embryo Culture System. The microscale SMART technology platform is designed to improve the in vitro manipulation, performance, and viability of embryos for the treatment of patients undergoing in vitro fertilization (IVF).

"We are delighted to be taking part in this important clinical trial," noted Dr. Thomas Pool Ph.D., H.C.L.D. of the Fertility Center of San Antonio and a trial investigator. "Infertility continues to be a major healthcare issue, with only about 30% of IVF cycles nationwide resulting in a live birth using today's procedure. Incept's SMART Embryo Culture System is an important technological advance in the industry and may therefore offer couples a much more efficient and reliable procedure for IVF."

The study will assess the SMART system's capacity to safely enhance morphological embryo development and survival rates at day three of development, in comparison to the existing practice of growing embryos in a conventional culture dish. The prospective, multi-center, randomized performance study, which will take place at three investigational sites, is expected to enroll approximately 400 to 600 embryos from up to 40 couples who have been diagnosed with infertility and are planning to undergo IVF and embryo transfer.

"We are very excited about the potential benefits of using the SMART culture system to improve IVF," said Christopher Bleck, President and Chief Executive Officer of Incept. "This is a key milestone for the Company, which we expect will lead to a second study in 2010 that will evaluate implantation and pregnancy rates using the SMART culture system."

About IVF and Incept BioSystems' SMART Embryo Culture System

IVF is a technique in which eggs are retrieved from a woman's ovary and inseminated, resulting in fertilized eggs which are then cultured in specialized laboratory conditions. It is the primary treatment for infertility today, common when other methods of achieving conception have failed. According to the Society for Reproductive Technology, in 2007, women in the U.S. underwent approximately 132,700 IVF cycles and it is estimated that there will be more than one million cycles worldwide in 2009.

Unlike the current IVF practice of culturing embryos in a static environment (i.e., a microdrop in a culture dish), Incept's microfluidic system brings embryologists a significant step closer to natural conditions by providing a continuous, refreshable culture microenvironment while using industry-standard IVF culture medium. It is believed that this dynamic environment may provide a beneficial physical stimulus to the embryos in addition to replenishing the embryos with fresh medium while removing metabolized waste products. Mouse and bovine studies conducted by researchers at the University of Michigan and at the Company have demonstrated that the use of this system improves the rate of embryo development so that a greater percentage of embryos achieve advanced stages of development.

About Incept BioSystems

Incept BioSystems, Inc., based in Ann Arbor, Michigan, is a privately-held medical device company leveraging its proprietary microscale SMART technology (System of Microfluidics for Assisted Reproductive Technology) platform to improve the in vitro manipulation, performance, and viability of high-value cells for the treatment of patients undergoing in vitro fertilization. The SMART System assisted reproduction device is a cell culture system that can mimic in vivo conditions and is the first microfluidic system that will address the demanding user requirements of fertility professionals while reproducing physiologic conditions ideal for embryo and oocyte culture in the Assisted Reproduction lab. For additional information about Incept BioSystems, visit the Company's website at: http://www.inceptbio.com.

SOURCE Incept BioSystems, Inc.


'/>"/>
SOURCE Incept BioSystems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
2. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
3. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
4. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
5. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
6. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
7. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
8. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
9. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
10. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
11. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
(Date:6/2/2017)... Mass. , June 2, 2017  NxStage Medical, ... renal care, today announced new findings demonstrating positive biochemical ... ® System One™. The data will be presented ... in Madrid, Spain . ... to Improve Home Dialysis Network in Europe ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... The parent company ... in employee engagement. Omaha-based C&A Industries, a national leader in staffing and ... in North America for 2017. The annual award, issued by Achievers, ...
(Date:6/28/2017)... Church, VA (PRWEB) , ... June 28, 2017 , ... ... http://www.fdanews.com/fdaeumdregs      , No matter on which side of the Atlantic devicemakers ... medical device regulations they have to follow. , In addition to the full text ...
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the highest mortality ... at least one person dies as a direct result from an eating disorder in ... qualified treatment providers. The iaedp Foundation meets this challenge by offering what has become ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces the participation of ... winning television series, scheduled to broadcast fourth quarter 2017. American Farmer airs Tuesdays at ... supplier of garden pea seed. As demand grew, the small company located in Moscow, ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... insurance management and financial planning assistance to clients in southern Montana, is announcing ... offered by Zoo Montana. , The outreach programs offered by Zoo Montana provide ...
Breaking Medicine News(10 mins):